To understand whether the downregulation of MYC and MCL1 in vitro translates to patients, the maximum extent of inhibition for MYC mRNA after the first dose of 30 mg enitociclib on C1D1 in patients with DH-DLBCL (n = 10, black lines) and other MYC+ NHL (n = 5, colored lines) whole blood was 89.6% (range, 73.6%–94.8%) and 82.3% (range, 69.9%–90.5%), respectively where maximal inhibition occurred 1–2 hours postdose. The gene discussed is MYC; the disease is non-Hodgkin lymphoma.